Showing results (31-40 of 65) with videos related to
Sort By:
Pageof 7
British Journal of Cancer|December 4, 2025
Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancerNoboru Yamamoto, Dong Yan, Vinod Ganju, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2014
Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancerMartin J Edelman, Ming T Tan, Mary J Fidler, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2026
Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L)Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, et al.The Oncologist|July 21, 2021
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid TumorsKhanh T Do, Laura Quan Man Chow, Karen Reckamp, et al.Science Translational Medicine|April 18, 2014
Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205Madhav V Dhodapkar, Mario Sznol, Biwei Zhao, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2020
Atezolizumab Plus Chemotherapy for First-Line Treatment of Nonsquamous NSCLC: Results From the Randomized Phase 3 IMpower132 TrialMakoto Nishio, Fabrice Barlesi, Howard West, et al.Journal for Immunotherapy of Cancer|August 3, 2024
Phase I studies of davoceticept (ALPN-202), a PD-L1-dependent CD28 co-stimulator and dual PD-L1/CTLA-4 inhibitor, as monotherapy and in combination with pembrolizumab in advanced solid tumors (NEON-1 and NEON-2)Diwakar Davar, Ludimila Cavalcante, Nehal Lakhani, et al.Lung Cancer (Amsterdam, Netherlands)|March 3, 2023
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS studyKeunchil Park, Joshua K Sabari, Eric B Haura, et al.Cell Reports. Medicine|December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART MoleculeAlexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.Pageof 7